When managing patients with XLH
CRYSVITA (burosumab injection) is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
XLH is a genetic disease affecting children into adulthood, characterized by hypophosphatemia due to increased fibroblast growth factor 23 (FGF23) levels.1,3-5
Not actual patients.
FGF23=fibroblast growth factor 23; XLH=X-linked hypophosphatemia.
† Comparative clinical significance has not been established.
References: 1. CRYSVITA (burosumab injection) Product Monograph. Kyowa Kirin Inc. 2. CRYSVITA (burosumab injection) Product Monograph. Kyowa Kirin Inc.3. Glorieux FH, et al. Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH). Orphanet J Rare Dis. 2022;17(1):30.
4. Haffner D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435-455. 5. Dahir K, et al. X-linked hypophosphatemia: A new era in management. J Endocr Soc. 2020;4(12):bvaa151.
